Ivermectin and moxidectin against soil-transmitted helminth infections |
| |
| Institution: | 1. Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland;2. University of Basel, Basel, Switzerland;1. Algal Resources Collection, MARBIONC, Center for Marine Science, University of North Carolina Wilmington, Wilmington, NC 28409, USA;2. Sorbonne Université, CNRS, UMR7144 Adaptation et Diversité en Milieu Marin, Ecology of Marine Plankton (ECOMAP), Station Biologique de Roscoff, 29680 Roscoff, France;1. Department of Microbiology and Immunology, Meakins-Christie Laboratories, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada;2. McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada;3. McGill Regenerative Medicine Network, Montreal, Quebec, Canada;4. Department of Pathology, McGill University and Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada;5. McGill Centre for Microbiome Research, Montreal, Quebec, Canada;1. Leiden University Center for Infectious Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands;2. Interventional Molecular Imaging laboratory, Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands;2. Department of Entomology, Plant Pathology and Nematology, University of Idaho, Moscow, Idaho 83844, USA;1. Southeastern Cooperative Wildlife Disease Study, College of Veterinary Medicine, University of Georgia, Athens, GA, USA;2. Warnell School of Forestry and Natural Resources, University of Georgia, Athens, GA, USA;1. Centre for Medical Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark |
| |
| Abstract: | Ivermectin and moxidectin, two macrocyclic lactones, are potent antiparasitic drugs currently registered and mainly used against filarial diseases; however, their potential value for improved soil-transmitted helminth (STH) control has been acknowledged. This review provides insights on recent studies evaluating the efficacy of ivermectin and moxidectin as single or coadministered therapy against human soil-transmitted helminthiases (including Strongyloides stercoralis infections) and on pharmacokinetic/pharmacodynamic parameters measured in treated populations. Furthermore, we discuss current gaps for research, highlight advantages – but also existing challenges – for uptake of ivermectin and/or moxidectin treatment schemes into routine STH control in endemic countries. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
